MODAFINIL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Modafinil, and when can generic versions of Modafinil launch?
Modafinil is a drug marketed by Alembic, Apotex, Appco, Aurobindo Pharma Ltd, Cadila, Hikma Pharms, Mylan Pharms Inc, Orbion Pharms, and Watson Labs Inc. and is included in nine NDAs.
The generic ingredient in MODAFINIL is modafinil. There are twenty-six drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the modafinil profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Modafinil
A generic version of MODAFINIL was approved as modafinil by ORBION PHARMS on September 26th, 2012.
Summary for MODAFINIL
US Patents: | 0 |
Applicants: | 9 |
NDAs: | 9 |
Finished Product Suppliers / Packagers: | 17 |
Raw Ingredient (Bulk) Api Vendors: | 85 |
Clinical Trials: | 164 |
Patent Applications: | 3,714 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for MODAFINIL |
Drug Sales Revenues: | Drug sales revenues for MODAFINIL |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for MODAFINIL |
What excipients (inactive ingredients) are in MODAFINIL? | MODAFINIL excipients list |
DailyMed Link: | MODAFINIL at DailyMed |
Recent Clinical Trials for MODAFINIL
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Kuwait University | Early Phase 1 |
Genuine Research Center, Egypt | Phase 1 |
Chemipharm Pharmaceutical Industries, Egypt | Phase 1 |
Pharmacology for MODAFINIL
Drug Class | Sympathomimetic-like Agent |
Physiological Effect | Central Nervous System Stimulation Increased Sympathetic Activity |